23:42 , Sep 14, 2017 |  BC Extra  |  Company News

Management tracks: SymCel, Taro, Akcea

SymCel Sverige AB (Spanga, Sweden) named Jesper Ericsson CEO. He was director of marketing and sales at BioLamina AB (Stockholm, Sweden). SymCel offers a cell-based assay for real-time monitoring of cell metabolism. Prescription and OTC...
03:27 , Feb 17, 2017 |  BioCentury  |  Finance

Tokyo connection

Remiges Ventures is entering the company creation business, with a strategic investment from the University of Tokyo that will provide a pipeline of potential spinouts. The final close of the firm’s Remiges BioPharma Fund L.P....
02:00 , Feb 14, 2017 |  BC Extra  |  Financial News

Remiges tops off $80M biotech fund

Remiges Ventures raised $10 million in the second and final close of Remiges BioPharma Fund L.P., bringing the fund's total to $80 million. New LP UTokyo Innovation Platform, the University of Tokyo's strategic investment arm,...
20:44 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Skin and skin structure infection (SSSI); Staphylococcus Cell culture and mouse studies suggest inhibiting the Staphylococcus aureus biosynthetic proteins tarO or tarH could help treat skin abscesses caused by methicillin-resistant S. aureus (MRSA) infection....
01:27 , Dec 30, 2016 |  BioCentury  |  Emerging Company Profile

Mining for substitutions

Riptide Bioscience Inc. has mined the sequences and structures of failed first-generation peptide therapeutics to engineer a new class of host defense peptides with amino acid substitutions that could make its candidates more effective in...
00:06 , Dec 3, 2016 |  BC Extra  |  Company News

Management tracks

Prescription and OTC pharma Taro Pharmaceutical Industries Ltd. (NYSE:TARO) said Uday Baldota will replace Kal Sundaram as its CEO, effective April 2017. Baldota is EVP and CFO at Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). Abhay...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Vanda, Taro Pharmaceutical deal

Vanda granted Taro non-exclusive, U.S. rights to manufacture and commercialize a generic version of Vanda’s Fanapt iloperidone, effective November 2027. The license settled patent litigation against Taro’s ANDA for the product. If Vanda obtains pediatric...
01:06 , Jul 1, 2016 |  BC Extra  |  Company News

Management tracks

Molecular diagnostics company Epigenomics AG (Xetra:ECX) named Gregory Hamilton CEO. He replaces CEO and CFO Thomas Taapken, who has left the company. Hamilton was CEO at AltheaDx Inc. (San Diego, Calif.). The company expects to...
07:00 , Jun 13, 2016 |  BioCentury  |  Finance

Small price of progress

Although European biotechs have long had a problem making progress on small series A rounds, InFlectis BioScience S.A.S. and co-lead investor Remiges Ventures expect that a €4.5 million ($5 million) infusion will get the biotech's...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: S. aureus wall teichoic acid biosynthesis protein tarO (tarO)

Infectious disease INDICATION: Staphylococcus In vitro and mouse studies identified inhibitors of S. aureus wall teichoic acid biosynthesis protein tarO that could help treat methicillin-resistant Staphylococcus aureus (MRSA) infection. Screening of a small molecule library...